<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635438</url>
  </required_header>
  <id_info>
    <org_study_id>TPC-CLT-002</org_study_id>
    <nct_id>NCT02635438</nct_id>
  </id_info>
  <brief_title>A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis.</brief_title>
  <acronym>TPC</acronym>
  <official_title>&quot;A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis &quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thinq Pharma-CRO Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unique Pharmaceuticals Ltd, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>THINQ Pharma CRO Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thinq Pharma-CRO Pte. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to compare the efficacy and safety of Clotrimazole troche/
      lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) vs. Clotrimazole Troche/
      Lozenges USP, 10 mg (Roxane Laboratories Inc., USA) in patients with oropharyngeal
      candidiasis, where this condition has been diagnosed by clinical examination and confirmed by
      fungal culture
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is Randomized, Double Blind, Parallel, Comparative study. Approximately 26 study
      sites across India will participate in this study to complete sample size of 360 randomized
      subjects in order to achieve at least 250 per-protocol (PP) subjects.

      Subjects would be assigned randomly to test product or reference product in 1:1 ratio.

      Subjects with confirmed oral candidiasis by KOH smear/candidal culture will be given study
      medication 5 times a day for 14 consecutive days.

      The schedule of the subject's visit at study site will be as follows:

        1. Visit 1 - Screening visit (-7 Days).

        2. Visit 2 - Randomization (Day 1).

        3. Visit 3 - Follow Up (Day 8 (+2)).

        4. Visit 4 - Follow Up (Day 15 (+2)).

        5. Visit 5 - Follow Up/ End of study (Day 21 (+/-4)) Subjects with complete resolution of
           signs and symptoms of Oral Candidiasis on Day 21 (+/-4) will be considered as treatment
           success.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>7 days after the end of the therapy, (Day 21(+/- 4)</time_frame>
    <description>Clinical cure i.e., complete resolution of all signs and symptoms of Oropharyngeal Candidiasis, 7 days after the end of the therapy, (Day 21(+/- 4)). Signs and Symptoms of Oral Candidiasis will be assessed using the Murray scale on day 21(+/- 4). According to the Murray Scale, lesion score 0 and symptom score 0 is considered as clinical cure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mycological Cure</measure>
    <time_frame>Day 15(+2) of therapy.</time_frame>
    <description>Mycological cure (negative culture and negative KOH for Candida species) at Day 15(+2) of therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Oropharyngeal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Product: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) 10mg troche 5 times a day for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Product: Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) troche 5 times a day for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unique Pharmaceutical Laboratories, India</intervention_name>
    <description>Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxane Laboratories Inc., USA</intervention_name>
    <description>Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Presence of specific signs and symptoms of Oropharyngeal Candidiasis, including
             erythematous areas, white patches(thrush), mouth pain, irritation, burning, glossitis,
             altered taste, pruritis, dysphagia and odynophagia.

          2. Clinical examination of oropharynx consistent with a diagnosis of oral candidiasis
             (such as creamy, white, curd-like patches of &quot;thrush&quot; or erythematous lesions on
             mucosal surfaces).

          3. Confirmation of Candidiasis by findings on direct microscopic examination (potassium
             hydroxide smear) consistent with Candida species or positive fungal culture for
             Candida species, with culture obtained in the 2 days preceding initiation of therapy
             with the study drug.

          4. Subjects who are able and willing to give Informed Consent.

        Exclusion Criteria:

          1. Female subjects who are pregnant, lactating or planning to become pregnant during the
             study period.

          2. Subjects diagnosed with disseminated candidiasis or requiring systemic antifungal
             therapy.

          3. Subjects diagnosed with hairy leukoplakia.

          4. Presence of only perioral lesions, e.g., angular chelitis.

          5. History of intolerance or sensitivity to clotrimazole (or other imidazole or azole
             compounds) or any constituent of Roxane ® or the generic Clotrimazole Troche/ Lozenges
             or unable to tolerate oral medication.

          6. Subjects having history of resistance to treatment with clotrimazole (Subject who are
             resistant to Clotrimazole after culture and sensitivity test have to be excluded from
             the study).

          7. Subjects who have received any oral or systemic antifungal therapy within fourteen
             (14) days prior to randomization.

          8. Subjects who have received any investigational therapy within 30 days prior to
             randomization.

          9. Subjects who have been diagnosed with any concomitant condition that, in the opinion
             of the investigator, could interfere with the evaluation of efficacy or safety, or
             would make it unlikely that the subject would complete the study.

         10. Subjects who have been treated with protease inhibitors for the first time within 30
             days.

         11. Subjects who have been taking medications known to have significant interaction with
             azoles (e.g., antacids, H2-receptor blockers, rifampin, phenytoin, carbamazepine,
             astemizole).

         12. Subjects who have a history of candidal prophylaxis with any azole antifungal
             medication.

         13. Any subject with recurrent Oropharyngeal Candidiasis.

         14. Any subject who is chronically infected with Candida.

         15. Any subject with baseline liver function tests greater than 3 times the upper limit of
             normal (ULN).

         16. CD4 cell count less than 200 cells/mm3. 17. Absolute neutrophil count less than
             500/mm3.

        18. Subject with history of Type II Diabetes Mellitus with Uncontrolled Blood Sugar levels.
        (I.e. Random Blood Sugar level &gt; 350).

        19. Suspected inability (or) unwillingness to comply with the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalini Kumar, Medical</last_name>
    <role>Study Director</role>
    <affiliation>Director Medical Services, Unique Pharmacutical Laboratories, India (A Division Of J. B. Chemicals and Pharmacuticals Limited)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kalpesh B Vispute, Medical</last_name>
    <phone>+912225816882</phone>
    <phone_ext>882</phone_ext>
    <email>kalpesh@thinqcro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikhil Varma</last_name>
    <phone>+912225816888</phone>
    <phone_ext>888</phone_ext>
    <email>nikhil.varma@thinqcro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grant Government Medical College &amp; Sir JJ group of Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Mohan Jagade</last_name>
      <phone>91-9323593627</phone>
      <email>mohanjagade@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Mohan Jagade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Curie Manavata Cancer Centre</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Suwarna Tambade</last_name>
      <phone>91-9130715188</phone>
      <email>drsuwarna@manavatacancercentre.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Suwarna Tambade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manas Hospital</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Bhushan Nemade</last_name>
      <phone>91-9766126162</phone>
      <email>manassuperspeciality@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Bhushan Nemade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gujrat Cancer and Research Institute</name>
      <address>
        <city>Ahmadabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Geeta Joshi</last_name>
      <phone>91-9824075707</phone>
      <email>dr.geetajoshi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Geeta Joshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCG Hospital</name>
      <address>
        <city>Ahmadabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Shamik Mehta</last_name>
      <phone>91-9879090765</phone>
      <email>mehta.shamik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Shamik Mehta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sujan Surgical Cancer Hospital &amp; Amravati cancer foundation</name>
      <address>
        <city>Amravati</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Dwarakadas Adwani</last_name>
      <phone>91-9823288672</phone>
      <email>dr.dgadwani1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Dwarakadas Adwani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Hedgewar Hospital</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Venkatesh Deshpande</last_name>
      <phone>91-9881736365</phone>
      <email>venkatesh-deshpande@hedgewar.org</email>
    </contact>
    <investigator>
      <last_name>Dr. Venkatesh Deshpande</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Ravi Meher</last_name>
      <phone>91-9968604237</phone>
      <email>ravimeher@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ravi Meher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahaveer Cancer Hospital and Research Centre</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Tej Prakash Soni</last_name>
      <phone>91-9602240611</phone>
      <email>bmchrcclinicaltrial@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Tej Prakash Soni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chittaranjan National Cancer Institute</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. K K Mukherjee</last_name>
      <phone>91-9830115905</phone>
      <email>kkmukherjee4u@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. K K Mukherjee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saroj Gupta Cancer Centre &amp; Research Institute</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Dhrubajyoti Mukhopadhyay</last_name>
      <phone>91-9831142992</phone>
      <email>researchccwhri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Dhrubajyoti Mukhopadhyay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mandya institute of medical science</name>
      <address>
        <city>Mandya</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Hanumanth Prasad</last_name>
      <phone>91-9916856058</phone>
      <email>drmhp@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Hanumanth Prasad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Father Muller Medical College Hospital</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Savita Lasrado</last_name>
      <phone>91-9945361819</phone>
      <email>savita_menezes@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Savita Lasrado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Devendra Chaukar</last_name>
      <phone>91-9820506232</phone>
      <email>dchaukar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Devendra Chaukar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Government Medical Colllege Nagpur</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Kalpana Dasgupta</last_name>
      <phone>91-9822229496</phone>
      <email>drkalpanadasgupta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Kalpana Dasgupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shree hospital and critical care centre</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ashish Chikhale</last_name>
      <phone>91-9850853253</phone>
      <email>shreehospitalcriticalcare@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ashish Chikhale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Ajay Swaroop</last_name>
      <phone>91-9811021911</phone>
      <email>swaroopent@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ajay Swaroop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashwin Medical Foundations Moraya Multispeciality Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ravindra Kulkarni</last_name>
      <phone>91-9422300251</phone>
      <email>drravindrakulkarni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ravindra Kulkarni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital and Research Centre</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Bharat Purandare</last_name>
      <phone>91-9923456046</phone>
      <email>bharatpurandare@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Bharat Purandare</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.D.E.AS Ayurved Rugnalaya &amp; Sterling Multispeciality Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Rakesh Neve</last_name>
      <phone>91-9881143140</phone>
      <email>rakesh.neve@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Rakesh Nave</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Institute of Medical Science and RIMS Government Hospital</name>
      <address>
        <city>Srikakulam</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. BLN Prasad</last_name>
      <phone>91-9848211931</phone>
      <email>amcmedicine@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. BLN Prasad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apple Hospital</name>
      <address>
        <city>Surat</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Ghanshyam N Patel</last_name>
      <phone>91-9376913131</phone>
      <email>drgnpatelonco@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ghanshyam N Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asian Institute of Medical Science</name>
      <address>
        <city>Thane</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Neha Pangam</last_name>
      <phone>91-9833723155</phone>
      <email>nehapangam@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Neha Pangam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kailash cancer hospital and research center</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Shehnaz Kanthariya</last_name>
      <phone>91-9537511001</phone>
      <email>shehnazkantharia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Shehnaz Kanthariya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College and S.S.G Hospital</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Vimal Batra</last_name>
      <phone>91-9825350509</phone>
      <email>vimalbatra@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Vimal Batra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.B.K.S. Medical Institute &amp; Research Centre</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ajay George</last_name>
      <phone>91-8980178187</phone>
      <email>doc-ajay@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ajay George</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oropharyngeal Candidiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

